Cyteir adds $80M to steer to Phase 2 with lead cancer drug, then maybe an IPO

February 11, 2021 Auto Bot BioPharma, biopharma nl, biotech IPO, cancer, Pharma, Startups 0

dna, genomics

Phase 2 testing of Cyteir’s lead cancer drug candidate later is slated to start later this year. The Series C round of funding includes crossover investors, whose involvement is a sign a biotech is preparing for an IPO.